Search Results for: regulation

By Kuldip K. Ambastha On Thursday, January 5, 2023, the stock of NovoCure Limited (NVCR), an oncology company, rose by +68.5% for the trading day. The LUNAR study has shown that a medical device developed by NovoCure is able to improve, in a statistically significant way, the prospect of survival for people with late-stage lung …

Continue reading “What Caught Our Attention in the Investment World? – Week of January 3-6, 2023”

By Kuldip K. Ambastha The stock of BeiGene, Ltd. (BGNE), a commercial stage biopharmaceutical company focused on cancer treatment drugs, saw a +20.5% increase in price per share on Wednesday, October 12, 2022. Brukinsa (zanubrutinib) in its Phase 3 trial data showed highly positive results in people with chronic lymphocytic leukemia (CLL) or small lymphocytic …

Continue reading “What Caught Our Attention in the Investment World? – Week of October 10-14, 2022”

By Kuldip K. Ambastha The stock of Tilray Brands, Inc. (TLRY), a Canadian company with an extensive presence worldwide in the cannabis sector, delivered +14.6% on Thursday, July 14, 2022 followed by -10.6% on Friday, July 15, 2022. Politics plays a big role in the success or failure of any cannabis sector company. On Thursday, …

Continue reading “What Caught Our Attention in the Investment World? – Week of July 11-15, 2022”

By Kuldip K. Ambastha Novavax, Inc. (NVAX), a clinical-stage vaccine company, had its stock price fall by -17.2% per share on Thursday, June 9, 2022. (See past coverage if needed: “What Caught Our Attention in the Investment World? – Week of December 27-31, 2021; By Kuldip K. Ambastha.”) In 1Q2022, earnings per share plus total …

Continue reading “What Caught Our Attention in the Investment World? – Week of June 6-10, 2022”

By Kuldip K. Ambastha Sea Limited (SE), a technology company based in Singapore with operations in digital entertainment, e-commerce, and digital financial services, was in the news during the past trading week. The stock of Sea Limited had four negative daily returns plus one positive daily return for the trading week, with a -11.4% loss …

Continue reading “What Caught Our Attention in the Investment World? – Week of January 3-7, 2022”

By Kuldip K. Ambastha Novavax, Inc. (NVAX), a clinical-stage vaccine company, had four negative daily returns and one positive daily return for its shares during this past trading week per the table displayed here. Worldwide, the coronavirus pandemic continues to be a serious public health issue, especially through the Delta and Omicron COVID-19 variants. Novavax …

Continue reading “What Caught Our Attention in the Investment World? – Week of December 27-31, 2021”

By Kuldip K. Ambastha During this past trading week, stocks in the casino sector suffered greatly. After positive daily returns on Monday, September 13, negative daily returns were mostly seen for the rest of the trading week for Las Vegas Sands Corporation (LVS) and Wynn Resorts, Limited (WYNN) per the table seen above (except for …

Continue reading “What Caught Our Attention in the Investment World? – Week of September 13-17, 2021”

By Kuldip K. Ambastha DiDi Global Inc. (DIDI) is a Chinese vehicle for hire company, with corporate headquarters in Beijing. The company went public on Wednesday, June 30, 2021, on the New York Stock Exchange (NYSE). On Tuesday, July 6, 2021, the stock had a significant -19.6% decline for the day. The Cyberspace Administration of …

Continue reading “What Caught Our Attention in the Investment World? – Week of July 6-9, 2021”

By Kuldip K. Ambastha Peloton Interactive, Inc. (PTON) is a luxury exercise gear maker which was in the news prominently during this past trading week. The company was also mentioned on this website once before (What Caught Our Attention in the Investment World? – Week of December 23-27, 2019). On Wednesday, May 5, 2021, the …

Continue reading “What Caught Our Attention in the Investment World? – Week of May 3-7, 2021”

By Kuldip K. Ambastha and Anil K. Ambastha On October 22, 2019, Biogen Inc. (BIIB) delivered a 26.1% return for the day. This was the stock’s largest one-day percentage return in 23 years. Its Alzheimer’s drug (aducanumab) had previously been written off as a failure, but now will be getting a second chance at approval …

Continue reading “What Caught Our Attention in the Investment World? – Week of October 21-25, 2019”